A plain language summary of the CAPItello-291 study: Capivasertib in hormone receptor-positive advanced breast cancer.

Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortés J, Gomez HL, Hu X, Jhaveri K, Krivorotko P, Loibl S, Murillo SM, Park YH, Sohn JH, Toi M, Tokunaga E, Yousef S, Zhukova L, de Bruin E, Grinsted L, Schiavon G, Foxley A, Rugo HS

Open source

DOI: 10.1080/14796694.2024.2390791
Published: 2024
Container: Future oncology (London, England)
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1080/14796694.2024.2390791,
  title = {A plain language summary of the CAPItello-291 study: Capivasertib in hormone receptor-positive advanced breast cancer.},
  author = {Turner NC and Oliveira M and Howell SJ and Dalenc F and Cortés J and Gomez HL and Hu X and Jhaveri K and Krivorotko P and Loibl S and Murillo SM and Park YH and Sohn JH and Toi M and Tokunaga E and Yousef S and Zhukova L and de Bruin E and Grinsted L and Schiavon G and Foxley A and Rugo HS},
  year = {2024},
  journal = {Future oncology (London, England)},
  doi = {10.1080/14796694.2024.2390791},
  url = {https://doi.org/10.1080/14796694.2024.2390791}
}

RIS

TY  - JOUR
TI  - A plain language summary of the CAPItello-291 study: Capivasertib in hormone receptor-positive advanced breast cancer.
AU  - Turner NC
AU  - Oliveira M
AU  - Howell SJ
AU  - Dalenc F
AU  - Cortés J
AU  - Gomez HL
AU  - Hu X
AU  - Jhaveri K
AU  - Krivorotko P
AU  - Loibl S
AU  - Murillo SM
AU  - Park YH
AU  - Sohn JH
AU  - Toi M
AU  - Tokunaga E
AU  - Yousef S
AU  - Zhukova L
AU  - de Bruin E
AU  - Grinsted L
AU  - Schiavon G
AU  - Foxley A
AU  - Rugo HS
PY  - 2024
JO  - Future oncology (London, England)
DO  - 10.1080/14796694.2024.2390791
UR  - https://doi.org/10.1080/14796694.2024.2390791
ER  -

APA

NC, T., M, O., SJ, H., F, D., J, C., HL, G., X, H., K, J., P, K., S, L., SM, M., YH, P., JH, S., M, T., E, T., S, Y., L, Z., E, D. B., L, G., G, S., A, F., & HS, R. (2024). A plain language summary of the CAPItello-291 study: Capivasertib in hormone receptor-positive advanced breast cancer.. Future oncology (London, England). https://doi.org/10.1080/14796694.2024.2390791

Source records

pubmed · retrieved 2026-09-26T11:16:08.830Z